The RMAT designation and strong Phase 2a data significantly de-risk the regulatory and clinical path for AlloNK in refractory RA. Traders should watch for the initiation of the Phase 3 trial later in 2026 and any partnership or licensing interest, as the off-the-shelf NK cell therapy could capture a large share of the autoimmune cell therapy market. The cash runway into 2029 reduces near-term dilution risk.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 8 $6.80entry
- T+1 · 5mo ago +6.91%α +7.21% · $7.27
- T+5 · 5mo ago +35.00%α +32.89% · $9.18
- T+20 · 4mo ago +38.82%α +37.19% · $9.44
- T+60 · 3mo ago +66.32%α +62.81% · $11.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Artiva Biotherapeutics presented positive clinical data for AlloNK (AB-101) at EULAR 2026, including a 71% ACR50 response at six months in refractory RA patients from its Phase 2a basket trial, and received FDA RMAT designation for AlloNK plus rituximab in refractory RA. The company plans to initiate a Phase 3 registrational trial in 2026, with cash runway extended into 2029 from a recent financing. These developments are bullish for the stock as they de-risk the regulatory path and validate the therapeutic potential in a large autoimmune market.
Key Facts
- FDA granted RMAT designation to AlloNK plus rituximab for refractory RA, providing expedited development and review benefits.
- 71% of patients in the company-sponsored Phase 2a basket trial achieved ACR50 response at six months.
- No CRS, ICANS, AlloNK-related serious adverse events, or treatment discontinuations due to AEs in 55 autoimmune patients.
- Complete B-cell depletion by Day 13 in all 28 evaluable RA patients using a high-sensitivity assay.
- Company plans to initiate a Phase 3 registrational trial in refractory RA in 2026.
- Cash runway extended into 2029 from recent financing.
- Data presented across five abstracts at EULAR 2026, including late-breaking oral presentation covering 31 patients.
Financial Impact
No financial figures provided in the press release. RMAT designation and positive Phase 2a data support a potential multi-billion-dollar market opportunity in refractory RA, but no revenue or deal values are disclosed.
Risk Factors
- Phase 3 trial may fail to replicate Phase 2a results in a larger, more diverse patient population.
- Competition from CD19 CAR-T therapies and other B-cell depleting agents could limit market share.
- Manufacturing scalability and outpatient administration remain to be proven at commercial scale.
- Regulatory approval is not guaranteed despite RMAT designation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307910 |
Track record
33 reports on ARTV
10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +34.74% at T+20 after the Sep 9, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers